Shaohui He

Shaohui He

Auto-generated profile, based on publicly available information

Shaohui He

Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
MYMengchen Yin
Mengchen Yin
QHQuan Huan
Quan Huan
ZSZhengwang Sun
Zhengwang Sun
SHShaohui He
Shaohui He
YXYe Xia
Ye Xia
JXJianru Xiao
Jianru Xiao

10 May 2016 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
YMYifei Ma
Yifei Ma
WZWang Zhou
Wang Zhou
SHShaohui He
Shaohui He
WXWei Xu
Wei Xu
JXJianru Xiao
Jianru Xiao
Bone metastasis from cancer of unknown primary (BMCUP) brings poor survival prognosis and its management remains controversial. Sunitinib (SUTENT) proved effective in many sorts of solid tumors but has never been applied for patients with occult primary cancers, and there is no study to identify sensitive or resistant biomarkers for sunitinib therapy in CUP patients. An analysis was carried out to investigate the efficacy of sunitinib by multivariate survival analysis of 286 patients with BMCUP. We further carried out multivariate analysis to identify histological and clinical biomarkers that could predict sensitivity or resistance for sunitinib therapy. Of the 286 patients included from January 2011 to March 2016, sunitinib therapy proved effective to prolong survival in patients with BMCUP. Sensitive and resistant biomarkers were identified in histological specimen of patients receiving sunitinib therapy. Clinical factors were also identified that predict poor survival prognosis for sunitinib therapy. Sunitinib therapy proved effective to prolong survival in patients with BMCUP. Sensitive markers for sunitinib therapy include KDR positivity and early-developed treatment-induced hypertension. Resistance factors for sunitinib include VEGF positivity, CAIX positivity and squamous cell carcinoma pathology type. Prolonged symptom time and severe weight loss before therapy seemed to be associated with poor survival prognosis for sunitinib therapy.